LONDON – Immunocore Ltd. has done it again, landing a multitarget pact with Glaxosmithkline plc (GSK), featuring a combined price tag of £142 million (US$212 million) for preclinical development followed by up to £200 million (US$299 million) per program in clinical and commercialization milestones, and double-digit royalties on sales. Read More
LONDON – A mouse model for a subtype of colon cancer – genetically identical to the equivalent human cancer – is making it possible to screen drugs to find more effective treatments for that type of tumor. Read More
Shares in Cardio3 Biosciences SA performed strongly on their first day of trading, following a July 4 initial public offering (IPO) on the NYSE Euronext exchanges in Brussels and Paris that raised €23 million (US$29.6 million). Read More
Oncoethix SA raised CHF18 million (US$18.7 million) in a Series B round to move its bromodomain and extra-terminal (BET) inhibitor OTX015 into Phase II proof-of-concept studies in hematological malignancies. Read More
LONDON – Cancer immunotherapy specialist Scancell Holdings plc is looking to raise £6.5 million (US$9.7 million) in a placing and open offer, allowing it to expand an ongoing Phase I/II trial of its lead Immunobody product, SCIB1 , and to commence preclinical development of a second cancer vaccine platform, Moditope. Read More
The regulatory system for drugs in China has improved since officials put the head of the country's FDA to death six years ago for accepting bribes, but the struggle is still uphill for drug developers inside the country and those trying to gain entry. Read More
LONDON – Problems with the regulatory framework and a lack of coordination is holding back development of regenerative therapies, delaying both health and economic benefits. Changes are needed to give investors confidence and clear the path to commercialization, according to a report on regenerative medicine in the UK, published last week. Read More
• Nanobiotix SA, of Paris, said it secured €9 million (US$11.7 million) in funding from Bpifrance (formerly OSEO), of which €2.8 million is directly attributable to the company. Read More
